Thus, miR-126 can keep CD34+CD38− AML cells in a more primitive state by increasing the proportion of quiescent CD34+CD38− cells, thereby decreasing the overall proliferative output and differentiation of AML blasts. The gene discussed is CD34; the disease is acute myeloid leukemia.